Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

Acute Ankle Sprain Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Multi-dose, Pivotal Study to Determine the Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01874626
• Other study ID #: SST0225-US-010-001
• Status: Completed
• Phase: Phase 3
• Start date: June 2013
• Est. completion date: January 2014

Study information

• Verified date: January 2014
• Source: Strategic Science & Technologies, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be randomized into the study and will receive either the active treatment (SST-0225 ibuprofen cream), or matching placebo. Subjects will apply an amount equivalent to a 4 inch line of investigational product to the affected ankle approximately every 4-6 hours. At Visit 1 two doses will be applied at the site. All subsequent doses of the investigational product will be applied every 4 to 6 hours with a total of 4 doses in a 24 hour period. Duration of treatment with the investigational product is 7 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 305
• Est. completion date: January 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

1. Male and female subjects =16 years of age

2. Grade I or II acute ankle sprain injury within 24 hours prior to first use of investigational product.

1. Grade I: when the ligament is stretched but not torn and the anterior talofibular ligament is usually involved. The anterior drawer test is negative

2. Grade II: moderate sprain, which usually results in partial tears of the ligaments, primarily the anterior talofibular and possibly the calcaneofibular ligament. Ligamentous laxity may be present and there is moderate swelling

3. At screening (Visit 1), subject reported pain intensity score upon movement of = 5 on a 0-10 Numerical Rating Scale (NRS)

4. Subject's Assessment of Normal Function/Activity (must be > 2) at screening

5. Able to comply with the visit schedule

6. Able to apply the investigational product as directed

7. Females of childbearing potential must be willing to use an approved method of birth control during study participation. Subjects currently using any of the below mentioned contraception methods, must have used the method for a minimum of three months prior to study enrollment, and must be willing to continue its use (at the same dose) throughout the study.

1. Effective methods of birth control: e.g. prescription oral, vaginal or transdermal contraceptives; contraceptive implants or injections; intrauterine device; diaphragm/cervical cap/condom with spermicide

2. Other acceptable methods of birth control include: Postmenopausal or amenorrhea for one year, Surgically sterile (hysterectomy, tubal ligation, or oopherectomy), Premenarcheal

8. Able to speak, read and comprehend English and record requested measurements as outlined in the protocol

9. Subject must be able to read, understand, sign and date the informed consent document (and the subject assent form, if necessary) indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial - Exclusion Criteria:

Subjects meeting any of the following criteria will not be entered in the study:

1. Similar injury of the same joint within the last 6 months

2. Clinical evidence of complete rupture of ankle ligaments (third degree sprain)

3. Requirements for bed rest, hospitalization, or surgical intervention for the ankle injury

4. Evidence of fractures or non-removable full cast of any type

5. Presence of bilateral occurrence of ankle injury or ipsilateral ankle and/or knee injury

6. Open wound or infection at site of injury

7. Significant Skin irritation at the application site;

8. Use of longer half life NSAID within 12 hours prior to study entry (Appendix 4)

9. Does not agree to use only supplied investigational product and rescue medication for analgesia during the seven days of the study or expects to require analgesics during the study for pain other than for ankle pain

10. Presence or history of allergy or intolerance to aspirin, NSAIDs, acetaminophen or any of the excipients in the investigational product (L-Arginine hydrochloride, Glyceryl Stearate, Cetyl Alcohol, Squalane, Xanthan Gum, Isopropyl Myristate, Oleic Acid, Propylene Glycol, Polysorbate -20)

11. Medical conditions including: peptic ulcer disease; clinically important gastrointestinal, renal, or hepatic disease within the past 6 months; clinically significant cardiovascular disease not stable for the past 6 months; uncontrolled hypertension as indicated by systolic blood pressure greater than or equal to 160 mmHg or a diastolic blood pressure greater than or equal to 100 mm Hg; coagulation disorders or hematologic disease; history of seizures; or known, significant, pre-existing conditions that would affect the interpretation of any potential adverse reactions to the study medication

12. Known alcohol abuse, drug dependency, or history of significant psychiatric illness within the past 12 months

13. Females who are pregnant or lactating. -

Related Conditions & MeSH terms

• Acute Ankle Sprain
• Ankle Injuries
• Sprains and Strains

Intervention

Drug:
• Placebo
Placebo cream
• SST-0225 Topical Ibuprofen Cream
SST-0225 Topical Ibuprofen Cream

Locations

Country	Name	City	State
United States	Ce3	Guilford	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
Strategic Science & Technologies, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	24 Hour SPID	Tme weighted summed pain intensity on movement difference from baseline over the first 24 hours (SPID24) following the first application of study medication on Day 1	24 Hours
Secondary	Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief	• Time to onset of confirmed perceptible pain relief and onset of meaningful pain relief over the four-hour in-office phase of the study.	First 4 hours
Secondary	Mean change from baseline in subject reported pain intensity	• Mean change from baseline in subject reported pain intensity (at rest and on movement) and pain relief (on movement only) as assessed at 15 minutes, 30 minutes, and hourly up to 4 hours following the first application on Day 1.	First 4 hours
Secondary	Mean change from baseline in pain scores on movement	• Mean change from baseline in pain scores on movement at hours 6, 8, 10, 12, 20 and 24 hours over the first 24 hours.	First 24 hours
Secondary	Percent of subjects with > 15%, > 30% and > 50% reductions in pain intensity	• Percent of subjects with > 15%, > 30% and > 50% reductions in pain intensity from baseline at 24 hours.	First 24 hours
Secondary	Subject's global evaluation of investigational product	• Subject's global evaluation of investigational product evaluated at Days 2, 4 and 7 (or End-of-Study) based on a 5 point scale.	7 days
Secondary	Use of rescue medication including time to first use	• Use of rescue medication including time to first use (first 12 hours), proportion of subjects using rescue and amount of rescue medication used.	7 days
Secondary	Change from baseline in pain scores on movement	• Change from baseline in pain scores on movement at time of each dose on Days 2-7.	7 days
Secondary	Number and percent of patients with systemic and local (skin) self-reported adverse events	Number and percent of patients with systemic and local (skin) self-reported adverse events.	7 days